Close menu




May 18th, 2022 | 12:53 CEST

Big percentages thanks to platform strategy: Amazon.com, Defence Therapeutics, Nordex

  • Biotech
Photo credits: pixabay.com

A central principle of the platform economy is to bring together different user groups and thus create synergies. What sounds a bit dry quickly becomes interesting, especially from an investor's point of view. For example, when different car models are based on one and the same platform, or when several diseases can be effectively combated thanks to one and the same technology. The unique aspect for investors: If these synergies come to fruition and a business succeeds in scaling, high returns are possible. We cite three stocks as examples.

time to read: 4 minutes | Author: Nico Popp
ISIN: AMAZON.COM INC. DL-_01 | US0231351067 , DEFENCE THERAPEUTICS INC | CA24463V1013 , NORDEX SE O.N. | DE000A0D6554

Table of contents:


    Amazon: This giant never falters

    Amazon's business is a true success story. Having started as a book mail-order Company, Amazon has long since become a global empire. Decades ago, when founder Jeff Bezos was thinking about getting his foot in the door in eCommerce as quickly as possible, he was thinking about books. Books don't go bad, and they all have more or less the same format, making packaging and shipping easy. Amazon has long since gone much further and now sells everything. The Company has long since made its logistics and website available to third-party sellers. These compete on the Amazon platform and even pay to be placed prominently - a simple business model has evolved into multiple options.

    A few years ago, Amazon started to throw its own tech gadgets onto the market. Streaming boxes for TV, tablets and even smartphones were available from Amazon. Later, the smart assistant Siri was added. Of course, buying in the Amazon universe is straightforward with these gadgets. The Prime subscription service also entices customers to do everything via Amazon's services. Today, the Company is a retail giant with great tech power. Many other business models are conceivable in the Amazon universe. Despite losses of around 20%, investors should keep the stock in mind. However, there is no buying pressure.

    Defence Therapeutics: Many irons in the fire - CEO takes your questions

    What Amazon's website and logistics infrastructure is, Defence Therapeutics' Accum™ technology is. The biotech Company develops vaccines and also focuses on the treatment of diseases. Meanwhile, numerous patents are among the Company's intangible assets. Accum™ is a so-called antibody-drug conjugate (ADC) that can deliver conventional drugs into affected cells. This targeted approach ensures that the necessary dose can be reduced, which in turn can potentially increase the likelihood of drug approval. It is precisely in this area that it becomes clear why Accum™ technology can also be compared to a multi-tool. On the one hand, Defence Therapeutics is driving forward the development of vaccines against human papillomaviruses (HPV) and COVID-19 and is planning to launch corresponding studies possibly as early as the end of 2022. On the other hand, Accum™ can boost existing compounds, making them potentially useful.

    In an interview, Dr Moutih Rafei, Director and VP of Research and Development at Defence Therapeutics, made it clear that the technology could be open to other companies: "Almost every pharmaceutical company is working on ADCs - Genentech, Roche, AstraZeneca and many others. In Germany in particular, people may be familiar with the story of CureVac, whose COVID-19 vaccine was unfortunately unsuccessful due to problems with dosing. All of these companies are potential partners for us precisely because we can solve problems with dosing effectively and without undesirable side effects," Rafei said. In addition, there are considerations to use Accum™ on the one hand as a drug enhancer and at the same time as an effective drug, as the substance is considered highly toxic when used in a targeted manner. The areas of application for Defence Therapeutics and its technology are diverse and full of potential synergy effects, which may offer the potential for surprises. Collaborations that inject capital into the Company are also conceivable. May 19, Rafei will present his Company at 3:20 pm live at the International Investment Forum (IIF) via Zoom. There is no charge to participate, and questions are welcome. Interested investors should use this event for a deep dive.

    Nordex: Sentiment good, margin poor

    The Nordex share demonstrates that thorough due diligence is particularly important now - the stock has lost around 17.7% in the last three months despite the energy crisis and climate change. Last year, the research portal researchanalyst.com already showed where Nordex is failing: the margin is not right. High raw material costs and increasingly expensive transport make life difficult for Nordex. And this even though the Rostock-based wind turbine manufacturer tried to take countermeasures in good time with its Delta 4000 platform. In the meantime, Delta 4000 already accounts for a large share of new business. Further positive impulses are doubtful, which is reflected in the share price. Nordex is green, sustainable and unfortunately uninteresting for investors.


    The examples mentioned above show that not all platforms are the same. While the business at Amazon is already well developed, and the share can lose a few percent in the wake of the overall market without really getting into trouble, the new Delta 4000 platform at Nordex did not cause jubilation. What will happen to Defence Therapeutics in a few years is also still up in the air. However, what is certain is that the areas of application are diverse, and Accum™ has what it takes to generate income streams. In a market phase where growth is not expensive on the stock market, investors should do their homework and research - for example, on Thursday at the IIF, where 14 other high-profile decision-makers will join Defence. The live event is free of charge via zoom.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Nico Popp

    At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

    About the author



    Related comments:

    Commented by André Will-Laudien on November 6th, 2024 | 08:00 CET

    US election and the biotech sector – A hot November is on the cards! BioNTech, Pfizer, Nyxoah, Bayer or Evotec?

    • Biotechnology
    • Biotech
    • Pharma

    With anticipation building for both the Q3 earnings season and the US election results, the markets are in a wait-and-see mode. Democrat frontrunner Kamala Harris is said to be committed to continuing the successful policies of her predecessor Joe Biden. Of course, science, research and climate protection are in the spotlight. Her rival, Donald Trump, is said to be more concerned with strengthening the traditional economy, where automotive engineering, the defense industry and security companies come to the fore. Additionally, markets are looking to central banks for cues, as lower interest rates would be a boon for the biotech sector. Here are some investment ideas for dynamic investors in this promising climate.

    Read

    Commented by André Will-Laudien on November 5th, 2024 | 07:30 CET

    The tension is rising! Quarterly figures from BioNTech and Evotec – Doubling potential for BioNxt, Grenke and SMCI

    • Biotechnology
    • Biotech
    • Technology

    The reporting season has just started, and the first profit warnings are already here. Grenke warns of increasing provisions, Super Micro Computer is keen to submit figures, but the auditor has resigned. There is good news, however, from Evotec, BioNTech, and BioNxt, with their bottoming phases seemingly behind them. In an environment of falling interest rates, biotech stocks could now appear in a new light. Currently, everyone is looking west because the world's largest economic power is electing a new president. Once the uncertainty clears, markets may continue their positive trend. We have some interesting investment ideas in store.

    Read

    Commented by Juliane Zielonka on October 30th, 2024 | 07:45 CET

    Nyxoah, Bayer and Palantir - The billion-dollar precision medicine market: Why investors are now taking notice

    • Biotechnology
    • Biotech
    • medtech
    • Software
    • Pharma

    Precision medicine is revolutionizing global healthcare: Experts predict that this future market will reach over USD 175 billion by 2028, driven by the growing demand for individualized treatment methods. Three companies stand out in particular: Belgian medical technology company Nyxoah is developing a mask-free therapy for the 936 million people worldwide with sleep apnea with its Genio system, while Bayer AG is revolutionizing fertility treatment through real-time hormone monitoring through its partnership with Impli. With its foundry platform, technology leader Palantir enables pharmaceutical giant Sanofi to analyze the health data of over 300 million patients. These patient-centered innovations not only promise better treatment outcomes for millions of people but also present investors access to one of the most dynamic growth markets in the healthcare sector.

    Read